C12Y 306/05005
Dynamin gtpase
Official title: Dynamin GTPase (3.6.5.5)
C12Y306/05005 (Dynamin gtpase) appears on 14 US grants and 34 published applications in this corpus.
Search patents in C12Y- Granted patents
- 14
- Published applications
- 34
- Assignees
- 32
- Inventors
- 68
- Latest grant
- 26 May 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 2007 | 0 | 1 |
| 2008 | 0 | 1 |
| 2009 | 0 | 0 |
| 2010 | 1 | 1 |
| 2011 | 0 | 0 |
| 2012 | 0 | 0 |
| 2013 | 0 | 0 |
| 2014 | 1 | 0 |
| 2015 | 0 | 0 |
| 2016 | 0 | 1 |
| 2017 | 0 | 0 |
| 2018 | 0 | 2 |
| 2019 | 0 | 2 |
| 2020 | 2 | 1 |
| 2021 | 2 | 5 |
| 2022 | 3 | 3 |
| 2023 | 1 | 4 |
| 2024 | 1 | 3 |
| 2025 | 2 | 4 |
| 2026 | 1 | 6 |
By publication year. 2026 runs to 8 Oct.
Recent patents
- Treatment of optic atrophy26 May 2026US 12,637,676 B2PYC Therapeutics Limited
- OPA1 antisense oligomers for treatment of conditions and diseases24 Jun 2025US 12,338,437 B2Stoke Therapeutics, Inc.
- Products and methods for inhibition of expression of dynamin-1 variants15 Apr 2025US 12,275,941 B2Research Institute At Nationwide Children's Hospital
- Allele-specific silencing therapy for dynamin 2-related diseases12 Mar 2024US 11,926,829 B2Assoication Institut De Myologie
- OPA1 antisense oligomers for treatment of conditions and diseases14 Nov 2023US 11,814,622 B2Stoke Therapeutics, Inc.
- Hypoxia-Resistant Immune Cells for Sustained Persistence and Functionality in the Hypoxic Tumor Microenvironment1 Oct 2026US 2026/0297527 A1Universiteit Antwerpen
- Biomarkers for Long COVID7 May 2026US 2026/0126444 A1Szegedi TudomáNyegyetem
- Therapy by trans-splicing of opa1 pre-messenger rnas for the treatment of diseases associated with opa1 gene mutations23 Apr 2026US 2026/0109985 A1Centre National De La Recherche Scientifique
- New synthetic drugs for treating alzheimer's disease26 Mar 2026US 2026/0083826 A1Okinawa Institute of Science and Technology School Corporation
- Correction of alzheimer's disease pathology5 Mar 2026US 2026/0061064 A1
Most cited
By later US patents
- Allele-specific silencing therapy for Dynamin 2-related diseases3US 10,947,540 B2Association Institut De Myologie · 2021
- OPA1 antisense oligomers for treatment of conditions and diseases2US 11,814,622 B2Stoke Therapeutics, Inc. · 2023
- Dynamin 2 inhibitor for the treatment of centronuclear myopathies1US 10,647,986 B2Centre National De La Recherche Scientifique · 2020
- OPA1 antisense oligomers for treatment of conditions and diseases1US 12,338,437 B2Stoke Therapeutics, Inc. · 2025
- Dynamin mediated diseases and associated methods and products1US 7,670,817 B2The General Hospital Corporation · 2010